Apremilast

證據等級: L5

預測適應症: 10 個

Apremilast: From Psoriatic Arthritis to Rheumatoid Arthritis

One-Sentence Summary

Apremilast (Otezla) is an oral small-molecule PDE4 inhibitor approved in the US and EU for psoriatic arthritis and plaque psoriasis, but not yet marketed in Taiwan. The TxGNN model predicts it may be effective for Rheumatoid Arthritis (RA), with 6 clinical trials and 19 publications supporting this direction — though a key Phase 2 trial (n=237) was terminated early, indicating limited efficacy in the MTX-refractory population and no Phase 3 follow-up.

Note on prediction ranking: The top TxGNN-scored prediction for Apremilast is migraine disorder (score 98.66%, L5 — no clinical evidence). This report focuses on Rheumatoid Arthritis (TxGNN rank 3, score 98.09%, L2), which carries the strongest clinical evidence and the most actionable decision recommendation among all predicted indications.

Quick Overview

Item	Content
Original Indication	Psoriatic arthritis, plaque psoriasis (globally approved; not marketed in Taiwan)
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	98.09%
Evidence Level	L2
Taiwan Market Status	✗ Not marketed (0 authorizations)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Apremilast selectively inhibits phosphodiesterase type 4 (PDE4), the enzyme responsible for degrading intracellular cyclic AMP (cAMP). By blocking PDE4, apremilast elevates cAMP, activates protein kinase A (PKA), and prevents NF-κB nuclear translocation — thereby suppressing downstream production of TNF-α, IL-17, IL-23, and IL-1β. In vitro data from human RA synovial cells directly confirmed that apremilast inhibits spontaneous TNF-α secretion (PMID 20525198), and a collagen-induced arthritis mouse model demonstrated suppression of Th1/Th17 cells alongside enhanced Treg differentiation (PMID 30072998).

Rheumatoid arthritis shares the same core inflammatory axis as psoriatic arthritis — the condition for which apremilast is approved. Both diseases involve Th1/Th17 skewing, synovial macrophage overactivation, and excess cytokine production. This mechanistic overlap has already been tested in humans: a completed Phase 2 RCT (NCT01250548; PMID 25779750) evaluated apremilast directly in active RA, providing controlled efficacy and safety data.

However, the development trajectory carries a significant warning signal. The largest Phase 2 RA trial (NCT01285310, n=237) was terminated early — most likely due to insufficient efficacy in the MTX-inadequate refractory population — and NCT01204138 was withdrawn with zero enrollment. Apremilast did not advance to Phase 3 for RA. This pattern suggests its utility may be limited to a specific subpopulation: patients with mild-to-moderate RA who are MTX-intolerant, biologic-naïve, or in whom biologics are contraindicated.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01250548	Phase 2	Completed	34	Controlled trial (apremilast vs placebo) directly in active RA; assessed safety, time to response, and durability of effect — the most directly relevant completed trial for this indication
NCT01285310	Phase 2	Terminated	237	Two apremilast doses vs placebo in RA patients with inadequate MTX response; terminated early — likely due to insufficient efficacy; no Phase 3 followed, a critical negative signal
NCT01204138	Phase 2	Withdrawn	0	Crossover study of apremilast add-on to TNF inhibitor + MTX in active RA; withdrawn before any enrollment — further weakens the case for use in refractory RA
NCT00521339	Phase 2	Completed	31	Safety, pharmacodynamics, and PK characterisation of apremilast in inflammatory disease; provides key dosing and tolerability data underpinning subsequent RA trials
NCT01504113	N/A	Unknown	100	Psoriasis targeted therapy and microorganism interactions; indirect background on apremilast’s immunomodulatory breadth and infection-risk profile

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25779750	2015	Phase II RCT	Arthritis & Rheumatology	Apremilast vs placebo in active RA with inadequate MTX response; primary clinical efficacy and safety data — the pivotal published evidence for this repurposing direction
26097790	2014	PK/PD Study	Clin Pharmacol Drug Dev	Co-administration PK of apremilast + methotrexate in RA and PsA patients; no clinically significant pharmacokinetic interaction identified, supporting safe co-use
30072998	2018	Animal Model	Front Immunol	Apremilast suppressed Th1/Th17 cells and enhanced Treg differentiation in collagen-induced arthritis mouse model; direct mechanistic evidence for RA-relevant anti-inflammatory effect
20525198	2010	In Vitro / Mechanism	Arthritis Res Ther	Apremilast inhibited spontaneous TNF-α production from human RA synovial cells and ameliorated two murine arthritis models; foundational mechanism study
40283434	2025	Review	J Clin Med	Comparative review of rituximab, apremilast, and upadacitinib in inflammatory arthritis; most current overview of apremilast’s therapeutic context in the RA landscape
24797159	2014	Drug Approval Review	Drugs	First global approval review of apremilast; confirms RA was an active development target alongside PsA and psoriasis, and summarises the regulatory history
33403021	2020	Systematic Review	Ther Adv Musculoskelet Dis	Shared development of targeted therapies across autoimmune inflammatory diseases; supports the mechanistic plausibility and precedent for cross-indication repurposing
32453211	2021	Case Report	J Clin Rheumatol	Successful use of apremilast for rituximab-associated palmoplantar pustulosis in a seropositive RA patient; documents real-world safety and utility in an RA context
30917076	2019	Real-World Cohort	J Manag Care Spec Pharm	Adherence, persistence, and costs of high-cost anti-inflammatory drugs in RA; contextualises real-world patient behaviour with novel agents including apremilast
38499181	2024	Clinical Guideline	J Am Acad Dermatol	Perioperative management of systemic immunomodulatory agents (including apremilast) in psoriasis and PsA; safety guidance with direct applicability to any RA development programme

Taiwan Market Information

Apremilast is not currently marketed in Taiwan (0 TFDA authorizations on record). Globally, it is approved by the US FDA (2014) and EMA under the brand name Otezla for psoriatic arthritis in adults and moderate-to-severe plaque psoriasis. Any repurposing development targeting the Taiwan market for RA would require a de novo TFDA regulatory submission. The Taiwan SmPC and formal warning/contraindication data are not yet available for this evaluation.

Safety Considerations

MOA Data Gap: Detailed mechanism of action data is listed as unavailable in this evidence pack. From the included literature, apremilast is consistently characterised as a PDE4 inhibitor (PMID 20525198, 30072998, 24797159), with class-associated risks including nausea, diarrhoea, headache, and — importantly — neuropsychiatric effects (depression, suicidal ideation) known from the PDE4 inhibitor class.
Pregnancy Considerations: A 2025 scoping review (PMID 39895048) highlights incomplete data on tsDMARD pregnancy outcomes; apremilast’s reproductive safety in RA has not been separately characterised.
No Drug-Drug Interaction Data Found: The DDI query returned no results. CYP3A4 inducers (e.g. rifampicin) are known to reduce apremilast exposure based on global SmPC data; this should be confirmed before clinical use.

Please refer to the global Otezla SmPC for complete warnings, contraindications, and drug interaction information pending TFDA SmPC availability.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Apremilast has direct Phase 2 RCT evidence in RA (PMID 25779750; NCT01250548) with compelling mechanistic support from human synovial cell studies and animal models. However, development stalled after the larger NCT01285310 (n=237) was terminated — the drug did not reach Phase 3 for RA. The opportunity lies in a narrower, better-defined patient subgroup (MTX-intolerant, biologic-naïve, or mild-to-moderate RA) rather than in the refractory population where it has already shown insufficient effect.

To proceed, the following is needed:

Obtain and review the full published or unpublished results from NCT01250548 and NCT01285310, including the specific reason for termination and subgroup efficacy data
Define the target RA subpopulation where the benefit-risk profile is favourable (e.g. MTX-intolerant, early RA, or those with contraindications to biologics)
Obtain the Taiwan TFDA SmPC or global Otezla SmPC to complete warning, contraindication, and DDI assessment (currently listed as data gaps)
Confirm MOA data via DrugBank API (DB05676) to complete the mechanistic profile
Conduct a focused systematic review on apremilast in early or mild RA before designing any new clinical study
Review the 2025 pregnancy outcomes scoping review (PMID 39895048) to assess reproductive safety if the target population includes women of childbearing potential
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.